Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis

Abstract

Background:This study aims to assess oral alpha lipoic acid’s (ALA’s) safety and effectiveness in managing diabetic neuropathy.
Methods:A thorough search of the literature was conducted using PubMed, Google Scholar, and Embase databases, and the study was performed as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Results:Based on inclusion and exclusion criteria, nine randomized controlled trials (RCTs) comprising 1,345 subjects were selected. The results showed that ALA has shown significant reduction in glycated hemoglobin (HbA1C) [inverse variance (IV): –0.66, (–0.81 → –0.51) at 95% CI, p ＜ 0.00001, I² = 92%], neuropathy impairment score (NIS) [IV: –1.19, (–2.28 → –0.09) at 95% CI, p = 0.03, I² = 58%], along with improving the neuropathy symptoms and change (NSC) number [IV: –0.18, (–0.35 → –0.01) at 95% CI, p = 0.04, I² = 0%], NSC severity score [IV: –0.65, (–0.83 → –0.48) at 95% CI, p ＜ 0.00001, I² = 89%], total severity score (TSS) [IV: –0.43, (–0.59 → –0.27) at 95% CI, p ＜ 0.00001, I² = 98%], neurological disability score (NDS) [IV: –0.72, (–1.03 → –0.40) at 95% CI, p ＜ 0.00001, I² = 98%], vibration perception threshold (VPT) [IV: –0.35, (–0.50 → –0.19) at 95% CI, p ＜ 0.0001, I² = 96%] and global satisfaction [Mantel-Haenszel (M-H) odds ratio (OR): 3.51, (1.06 → 11.61) at 95% CI, p = 0.04, I² = 72%] when compared to the control or placebo group. However, ALA has not shown significant changes in motor nerve conduction velocity (MNCV) score [IV: 0.26, (–0.44 → 0.96) at 95% CI, p = 0.47, I² = 49%] and NIS-low limb (NIS-LL) [IV: –0.58, (–1.35 → 0.19) at 95% CI, p = 0.14, I² = 0%] when compared to the placebo group.
Discussion:Based on the available moderate to high-quality evidence, we can conclude that oral administration of ALA at doses of 600–1,800 mg may be beneficial in improving/alleviating the symptoms resulting from diabetic neuropathy.

Keywords

diabetic neuropathy / alpha lipoic acid / thioctic acid / RCTs

References

[1] Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J. 2006; 82: 95-100.

[2] Kamalarathnam SR, Varadarajan S. Diabetic peripheral neuropathy in diabetic patients attending an urban health and training centre. J Fam Med Prim Care. 2022; 11: 113-7.

[3] Jasmine A, Akila GV, Durai V, Anitha Rani M, Shriraam V, Samya V, et al. Correction to: Prevalence of peripheral neuropathy among type 2 diabetes mellitus patients in a rural health centre in South India. Int J Diabetes Dev Ctries. 2021; 41: 301.

[4] Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2163-96.

[5] Vinik AI, Nevoret M, Casellini C, Parson H. Diabetic Neuropathy. Endocrinol Metab Clin N Am. 2013; 42: 747-87.

[6] Yang K, Wang Y, Li Y, Chen Y, Xing N, Lin H, et al. Progress in the treatment of diabetic peripheral neuropathy. Biomed Pharmacother. 2022; 148: 112717.

[7] Khdour MR. Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol. 2020; 72: 863-72.

[8] Zakin E, Abrams R, Simpson DM. Diabetic Neuropathy. Semin Neurol. 2019; 39: 560-9.

[9] Hsieh R, Huang I, Chen C, Sung J. Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Nutrients. 2023; 15: 3634.

[10] Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003; 26: 770-6.

[11] Garcia-Alcala H, Santos Vichido CI, Islas Macedo S, Genestier-Tamborero CN, Minutti-Palacios M, Hirales Tamez O, et al. Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. J Diabetes Res. 2015; 2015: 1-8.

[12] Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res. 1999; 31: 171-9.

[13] Baicus C, Purcarea A, Von Elm E, Delcea C, Furtunescu FL. Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2024.

[14] Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924-6.

[15] Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64: 401-6.

[16] Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [Internet]. [cited 2025 Jan 10]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html

[17] Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999; 22: 1296-301.

[18] Vijayakumar APR, Kalshetti SM, Bhatt JK. Supplementation of A-Lipoic acid in diabetic peripheral neuropathy: A prospective open label randomized controlled trial. Int J Pharm Pharm Sci. 2014; 6: 90-3.

[19] Hemoglobin A1C [Internet]. StatPearls; [cited 2025 Jan 10]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549816/

[20] Yarlas A, Lovley A, Brown D, Vera-Llonch M, Khella S, Karam C. The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy. BMC Neurol. 2023; 23: 108.

[21] Nerve conduction velocity: Side effects and normal values [Internet]. London: Healthline Media; c2025 [cited 2025 Jan 10]. Available from: https://www.medicalnewstoday.com/articles/321721

[22] Dyck PJB, Coelho T, Waddington Cruz M, Brannagan III TH, Khella S, Karam C, et al. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Muscle Nerve. 2020; 62: 509-15.

[23] Bastyr EJ, Price KL, Bril V. Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005; 27: 1278-94.

[24] Abdelalim A, Afifi L, Ashour A, Al-Athwari A. Correlation between clinical neuropathy scores and nerve conduction studies in patients with diabetic peripheral neuropathy. Egypt J Neurol Psychiatry Neurosurg. 2016; 53: 248.

[25] Jung J, Kim MG, Kang YJ, Min K, Han KA, Choi H. Vibration Perception Threshold and Related Factors for Balance Assessment in Patients with Type 2 Diabetes Mellitus. Int J Environ Res Public Health. 2021; 18: 6046.

[26] Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006; 29: 2365-70.

[27] Tang J, Wingerchuk DM, Crum BA, Rubin DI, Demaerschalk BM. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist. 2007; 13: 164-7.

[28] Siddique N, Awais F, Shakil M, Sarwar S, Kakar NH, Ullah MI. Effect of anti-oxidant (α-lipoic acid) treatment on the improvement of diabetic neuropathic pain. RMJ. 2021; 46: 33-6.

[29] Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011; 34: 2054-60.

[30] El-Nahas MR, Elkannishy G, Abdelhafez H, Elkhamisy ET, El-Sehrawy AA. Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study. EMIDDT. 2020; 20: 1531-4.

[31] Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schütte K, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999; 16: 1040-3.

[32] Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic Acid and diabetic neuropathy. Rev Diabet Stud. 2009; 6: 230-6.

[33] Rani PU, Padmaja M, Sireesha K, Sravansandhya P. Alpha lipoic acid a boon for diabetic peripheral neuropathy: A systematic review and meta-analysis. Biomed Res. 2023; 34: 1-8.

[34] Casadei G, Filippini M, Brognara L. Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot Peripheral Neuropathy. Diseases. 2021; 9: 16.

[35] Nozawa K, Ikeda M, Kikuchi S. Association Between HbA1c Levels and Diabetic Peripheral Neuropathy: A Case-Control Study of Patients with Type 2 Diabetes Using Claims Data. Drugs - Real World Outcomes. 2022; 9: 403-14.

[36] Elbadawy AM, Abd Elmoniem RO, Elsayed AM. Alpha lipoic acid and diabetes mellitus: potential effects on peripheral neuropathy and different metabolic parameters. Alex J Med. 2021; 57: 113-20.

[37] Millan-Guerrero RO, Garcia-Ramirez AL, Trujillo-Hernandez B, Caballero-Hoyos R, Gonzalez-Perez O, Isais-Millan S, et al. Efficacy of α-lipoic acid in the treatment of diabetic polyneuropathy. A Randomized, Double-Blind Study. Glob Adv Res J Med Med Sci. 2018; 7: 214-20.

[38] Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJG. Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials. Int J Endocrinol. 2012; 2012: 1-8.

[39] Lv SL, Fang C, Hu J, Huang Y, Yang B, Zou R, et al. Assessment of Peripheral Neuropathy Using Measurement of the Current Perception Threshold with the Neurometer® in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2015; 109: 130-4.

[40] Medakkel AA, Sheela P. Vibration Perception Threshold Values and Clinical Symptoms of Diabetic Peripheral Neuropathy. J Clin Diagn Res. 2018; 12: LC20-3.

[41] Lekhanya PK, Mokgalaboni K. Exploring the effectiveness of vitamin B₁₂ complex and alpha-lipoic acid as a treatment for diabetes mellitus/neuropathy: a protocol for systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022; 12: e065630.

[42] Naik M, Vasudevan D, Mukaddam Q. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: Results of a pilot study. Ann Indian Acad Neurol. 2014; 17: 19-24.

[43] Didangelos T, Karlafti E, Kotzakioulafi E, Kontoninas Z, Margaritidis C, Giannoulaki P, et al. Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy. Nutrients. 2020; 12: 3254.

[44] Wang X, Lin H, Xu S, Jin Y, Zhang R. Alpha lipoic acid combined with epalrestat: a therapeutic option for patients with diabetic peripheral neuropathy. DDDT. 2018; 12: 2827-40.

[45] Zhao M, Chen JY, Chu YD, Zhu YB, Luo L, Bu SZ. Efficacy of epalrestat plus α-lipoic acid combination therapy versus monotherapy in patients with diabetic peripheral neuropathy: a meta-analysis of 20 randomized controlled trials. Neural Regen Res. 2018; 13: 1087-95.

[46] Xu Q, Pan J, Yu J, Liu X, Liu L, Zuo X, et al. Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Res Clin Pract. 2013; 101: 99-105.

[47] Tang C, Han R, Wu J, Fang F. Effects of baicalin capsules combined with α-lipoic acid on nerve conduction velocity, oxidative stress and inflammatory injury in patients with diabetic peripheral neuropathy. Am J Transl Res. 2021; 13: 2774-83.

[48] Gilron I, Robb S, Tu D, Holden RR, Jackson AC, Duggan S, et al. Randomized, double-blind, controlled trial of a combination of alpha-lipoic acid and pregabalin for neuropathic pain: the PAIN-CARE trial. Pain. 2023; 165: 461-9.